Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study also indicated that the combined treatments produced acceptable levels of toxicity.
The randomized, controlled trial studied a total of 147 women in Brazil with stage IIIB squamous cell cervical cancer. A stage IIIB classification indicates that the cancer has spread to the pelvic wall and/or the tumor has become large enough to affect kidney function. Each patient received external beam radiation of 45 Gy to the pelvic region in 25 fractions; 14.4 Gy boost to the compromised parametrium (the connective tissue and fat adjacent to the uterus); and HDRB in the amount of four weekly fractions of 7 Gy prescribed to point A (the crossing of the uterine artery and the ureter).
Seventy-five patients received only RT and HDRB treatment—the RT group, and 72 patients received RT and HDRB plus weekly intravenous doses of 40 mg/m2 of cisplatin during the pelvic radiotherapy sessions—the CHRT group. [Note: Some chemotherapy doses were determined based on body surface area (BSA), which doctors calculate using a patient's height and weight. BSA is expressed in meters squared (m2)]. The research was conducted from 2003 through 2010, with follow-up lasting until January 2013.
Kaplan-Meier survival curves were performed comparing the five-year, disease-free survival (DFS) and the overall survival (OS) of the RT and CHRT groups. Differences in survival were assessed utilizing the log-rank test. Patients in the CHRT group had significantly better DFS (Hazard Ratio (HR)=0.52, 95 percent Confidence Interval (CI) 0.28 to 0.98; p=0.04) and had a better OS, but without statistical significance (HR=0.67, 95 percent CI 0.37 to 1.183; p=0.16).
Toxicity levels, measured utilizing the Cooperative Group Common Toxicity Criteria of the Radiation Therapy Oncology Group, in the CHRT group were similar to those in the RT group, with grades 1 and 2 acute toxicity at 37.5 percent for CHRT group, and 28 percent for RT group (p=0.29). Late toxicity grades 3 and 4 were 9.7 percent for the CHRT and 3 percent for the RT group (p=0.29).
"In testing a new approach of chemotherapy with traditional external beam radiation therapy and high-dose-rate brachytherapy, we were extremely cautious about possible toxicity for the patients," said Antonio Zuliani, MD, lead author of the study and a radiation oncologist at Campinas State University in Campinas, Brazil. "We were pleased by an increase in local control and the very low toxicity rates. We believe that these results demonstrate that this combined treatment protocol is safe to offer to patients and provides some beneficial improvements—in disease-free survival and toxicity levels."
Explore further: Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy
More information: The abstract, "Efficacy of Concomitant Cisplatin Plus Radiotherapy and High Dose Rate Brachytherapy versus Radiotherapy Alone for Stage IIIB Epidermoid Cervical Cancer: A Ten-Year Randomized Controlled Trial," will be presented in detail during a scientific session at ASTRO's 55th Annual Meeting at 1:45 p.m. Eastern time on September 22, 2013.
Medical Xpress on facebook
Related Stories
Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy
59 seconds ago
Patients receiving radiotherapy (RT) for cancers in the pelvic region can experience diarrhea, a negative side effect of radiation treatment. Sulfasalazine, an oral tablet used to treat inflammation of the bowels, had been ...
Higher-dose RT results in inferior survival in patients with stage III lung cancer
May 29, 2013
In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall ...
Brachytherapy to treat cervical cancer declines in US, treatment associated with higher survival
Sep 11, 2013
A study by researchers at Brigham and Women's Hospital (BWH) found that brachytherapy treatment was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis ...
Palliative radiation use for lung cancer higher than advised
Jan 18, 2013
(HealthDay)—Half of patients with metastatic non-small-cell lung cancer (NSCLC) receive at least one course of palliative radiation therapy (RT), with younger patients and those who received chemotherapy ...
Encouraging outcomes for pediatric brain tumor patients treated with proton therapy
41 seconds ago
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented today at the American Society ...
Recommended for you
Proton therapy is a cost-effective treatment for pediatric brain tumor patients
22 seconds ago
Proton therapy, an external beam radiotherapy in which protons deliver precise radiation doses to a tumor and spare healthy organs and tissues, is cost-effective in treating medulloblastomas, fast-growing brain tumors that ...
Encouraging outcomes for pediatric brain tumor patients treated with proton therapy
41 seconds ago
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented today at the American Society ...
Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy
59 seconds ago
Patients receiving radiotherapy (RT) for cancers in the pelvic region can experience diarrhea, a negative side effect of radiation treatment. Sulfasalazine, an oral tablet used to treat inflammation of the bowels, had been ...
Researchers identify proteins that may help brain tumors spread
29 minutes ago
Scientists at the University of Alabama at Birmingham have identified a molecular pathway that seems to contribute to the ability of malignant glioma cells in a brain tumor to spread and invade previously ...
Simple, two-question survery accurately screens cancer patients for depression
49 minutes ago
Cancer patients can be accurately screened for major depression with a simple two-question survey, according to a study presented Sept. 23 at the American Society for Radiation Oncology's 55th Annual Meeting.
Research to change how breast cancer treated
1 hour ago
(Medical Xpress)—Research from the newly formed Cambridge Cancer Centre, a collaboration between the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK and ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study also indicated that the combined treatments produced acceptable levels of toxicity.
The randomized, controlled trial studied a total of 147 women in Brazil with stage IIIB squamous cell cervical cancer. A stage IIIB classification indicates that the cancer has spread to the pelvic wall and/or the tumor has become large enough to affect kidney function. Each patient received external beam radiation of 45 Gy to the pelvic region in 25 fractions; 14.4 Gy boost to the compromised parametrium (the connective tissue and fat adjacent to the uterus); and HDRB in the amount of four weekly fractions of 7 Gy prescribed to point A (the crossing of the uterine artery and the ureter).
Seventy-five patients received only RT and HDRB treatment—the RT group, and 72 patients received RT and HDRB plus weekly intravenous doses of 40 mg/m2 of cisplatin during the pelvic radiotherapy sessions—the CHRT group. [Note: Some chemotherapy doses were determined based on body surface area (BSA), which doctors calculate using a patient's height and weight. BSA is expressed in meters squared (m2)]. The research was conducted from 2003 through 2010, with follow-up lasting until January 2013.
Kaplan-Meier survival curves were performed comparing the five-year, disease-free survival (DFS) and the overall survival (OS) of the RT and CHRT groups. Differences in survival were assessed utilizing the log-rank test. Patients in the CHRT group had significantly better DFS (Hazard Ratio (HR)=0.52, 95 percent Confidence Interval (CI) 0.28 to 0.98; p=0.04) and had a better OS, but without statistical significance (HR=0.67, 95 percent CI 0.37 to 1.183; p=0.16).
Toxicity levels, measured utilizing the Cooperative Group Common Toxicity Criteria of the Radiation Therapy Oncology Group, in the CHRT group were similar to those in the RT group, with grades 1 and 2 acute toxicity at 37.5 percent for CHRT group, and 28 percent for RT group (p=0.29). Late toxicity grades 3 and 4 were 9.7 percent for the CHRT and 3 percent for the RT group (p=0.29).
"In testing a new approach of chemotherapy with traditional external beam radiation therapy and high-dose-rate brachytherapy, we were extremely cautious about possible toxicity for the patients," said Antonio Zuliani, MD, lead author of the study and a radiation oncologist at Campinas State University in Campinas, Brazil. "We were pleased by an increase in local control and the very low toxicity rates. We believe that these results demonstrate that this combined treatment protocol is safe to offer to patients and provides some beneficial improvements—in disease-free survival and toxicity levels."
Explore further: Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy
More information: The abstract, "Efficacy of Concomitant Cisplatin Plus Radiotherapy and High Dose Rate Brachytherapy versus Radiotherapy Alone for Stage IIIB Epidermoid Cervical Cancer: A Ten-Year Randomized Controlled Trial," will be presented in detail during a scientific session at ASTRO's 55th Annual Meeting at 1:45 p.m. Eastern time on September 22, 2013.
Medical Xpress on facebook
Related Stories
Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy
59 seconds ago
Patients receiving radiotherapy (RT) for cancers in the pelvic region can experience diarrhea, a negative side effect of radiation treatment. Sulfasalazine, an oral tablet used to treat inflammation of the bowels, had been ...
Higher-dose RT results in inferior survival in patients with stage III lung cancer
May 29, 2013
In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall ...
Brachytherapy to treat cervical cancer declines in US, treatment associated with higher survival
Sep 11, 2013
A study by researchers at Brigham and Women's Hospital (BWH) found that brachytherapy treatment was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis ...
Palliative radiation use for lung cancer higher than advised
Jan 18, 2013
(HealthDay)—Half of patients with metastatic non-small-cell lung cancer (NSCLC) receive at least one course of palliative radiation therapy (RT), with younger patients and those who received chemotherapy ...
Encouraging outcomes for pediatric brain tumor patients treated with proton therapy
41 seconds ago
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented today at the American Society ...
Recommended for you
Proton therapy is a cost-effective treatment for pediatric brain tumor patients
22 seconds ago
Proton therapy, an external beam radiotherapy in which protons deliver precise radiation doses to a tumor and spare healthy organs and tissues, is cost-effective in treating medulloblastomas, fast-growing brain tumors that ...
Encouraging outcomes for pediatric brain tumor patients treated with proton therapy
41 seconds ago
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented today at the American Society ...
Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy
59 seconds ago
Patients receiving radiotherapy (RT) for cancers in the pelvic region can experience diarrhea, a negative side effect of radiation treatment. Sulfasalazine, an oral tablet used to treat inflammation of the bowels, had been ...
Researchers identify proteins that may help brain tumors spread
29 minutes ago
Scientists at the University of Alabama at Birmingham have identified a molecular pathway that seems to contribute to the ability of malignant glioma cells in a brain tumor to spread and invade previously ...
Simple, two-question survery accurately screens cancer patients for depression
49 minutes ago
Cancer patients can be accurately screened for major depression with a simple two-question survey, according to a study presented Sept. 23 at the American Society for Radiation Oncology's 55th Annual Meeting.
Research to change how breast cancer treated
1 hour ago
(Medical Xpress)—Research from the newly formed Cambridge Cancer Centre, a collaboration between the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK and ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment